Is Broach Lifecare overvalued or undervalued?

As of 20 August 2025, the valuation grade for Broach Lifecare has moved from risky to attractive, indicating a significant improvement in its financial standing. The company is currently considered undervalued. Key ratios include a PE Ratio of 15.42, an EV to EBITDA of 15.35, and a ROCE of 13.19%.
In comparison to its peers, Broach Lifecare's valuation metrics stand out favorably; for instance, Max Healthcare has a PE Ratio of 99.04 and Apollo Hospitals has a PE Ratio of 71.94, both indicating much higher valuations. Notably, Broach Lifecare's PEG Ratio is 0.00, suggesting potential for growth relative to its price. Additionally, the company's recent stock performance has outpaced the Sensex, with a 1-week return of 18.14% compared to the Sensex's 1.64%, reinforcing the attractiveness of its current valuation.